Clinical Trials Logo

Clinical Trial Summary

This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in greater reduction of sUA compared to placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02078219
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 2
Start date January 5, 2014
Completion date March 13, 2015

See also
  Status Clinical Trial Phase
Completed NCT06196580 - PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval Phase 1